SCHEMBL4049235

SCHEMBL4049235

CC(C[CH]C(=O)N1CCC2C1C(=O)CN2S(=O)(=O)c1ccccc1)C(N)=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
HSD11B1 P28845 3/20 0.37
ALDH1A1 P00352 2/20 0.36
CTSK P43235 2/20 0.36
CYP3A4 P08684 2/20 0.36
CYP2C19 P33261 2/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
MMP2 P08253 2/20 0.35
ANPEP P15144 1/20 0.35
MMP1 P03956 1/20 0.35
MMP3 P08254 1/20 0.35
MMP9 P14780 1/20 0.35
MMP8 P22894 1/20 0.35
MMP12 P39900 1/20 0.35
MMP13 P45452 1/20 0.35
MMP14 P50281 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4045677 0.91 HSD11B1 (0.34) HSD11B1
SCHEMBL4037609 0.90 CTSK (0.31) TSHRCTSKCYP3A4CYP2C19L3MBTL1
SCHEMBL4039217 0.89 HSD17B10 (0.40) TSHRKMT2AALDH1A1
SCHEMBL4044364 0.89 AKR1C3 (0.31) TSHRCYP3A4CYP2C19L3MBTL1CYP2D6
SCHEMBL4041823 0.86 CTSK (0.39) CTSK
SCHEMBL4042644 0.85 CTSK (0.33) CTSK
SCHEMBL6209388 0.84 CTSK (0.32) CTSK
SCHEMBL4048376 0.83 CTSK (0.51) HSD11B1ALDH1A1CTSK
SCHEMBL4039452 0.82 CTSK (0.32) CTSK
SCHEMBL4044726 0.82 PARP1 (0.34) KMT2AALDH1A1CTSKL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1546150-B1 PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES AMURA THERAPEUTICS LTD (GB) 2009-03-04 EP claimed
US-20060100431-A1 Biologically active compounds AMURA THERAPEUTICS LIMITED (GB) 2006-05-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100431-A1 Biologically active compounds SOST, CTSK, CTSS TSHR 1023/4885MEN1 3247/4885KMT2A 3867/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.